Are memantine, methylphenidate and donepezil effective in sparing cognitive functioning after brain irradiation?
Rosa Wartena , Dieta Brandsma , José Belderbos
Journal of Cancer Metastasis and Treatment ›› 2018, Vol. 4 : 59
One strategy to reduce neurocognitive deterioration in patients after brain irradiation is the use of neuroprotective medication. To generate up-to date knowledge regarding neuroprotective agents we performed a systematic review on the clinical effectiveness of three agents that were reported to have neuroprotective characteristics: memantine, methylphenidate and donepezil. The use of memantine after brain irradiation showed a delay in cognitive deterioration, although at 24 weeks this did not reach significance (P = 0.059). Lack of significance is likely to be the result of the limited statistical power of 35% and memantine did show significant differences in secondary outcomes. The study on methylphenidate was not conclusive. Donepezil revealed significant differences in a few cognitive tests however no difference in global cognition was found. In addition, larger effects were observed in individuals with greater cognitive dysfunction prior to treatment.
Memantine / donepezil / methylphenidate / brain irradiation / neuroprotection / whole brain irradiation / neuroprotective agent / lung cancer
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
Levels of evidence..BJU Int2011;107:870 |
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
/
| 〈 |
|
〉 |